Pharma


  • Charlotte Owens, vice president, head of the Center for Health Equity and Patient Affairs, Takeda
    Image attribution tooltip
    Permission granted by Takeda
    Q&A

    Takeda’s global quest for health equity

    Takeda’s Center for Health Equity and Patient Affairs is built to address health inequality around the world and aims to raise the bar for the pharma industry.

    By Dec. 8, 2022
  • A man in a suit looking at the camera
    Image attribution tooltip
    Courtesy of Biogen

    10 noteworthy pharma leadership shake-ups this year

    From GSK to Roche to Biogen, these were the most impactful executive changes at leading pharma companies in 2022.

    By Dec. 7, 2022
  • Professional headshot of Mahesh Karande
    Image attribution tooltip

    Permission granted by Mahesh Karande

    Profile

    Chasing a ‘holy grail’ cancer gene

    Omega Therapeutics’ president and CEO Mahesh Karande on its attempts to drug the elusive c-Myc gene.

    By Alexandra Pecci • Dec. 6, 2022
  • Bill Mezzanotte headshot
    Image attribution tooltip
    Permission granted by CSL
    Q&A

    A historic approval could transform CSL from being ‘the biggest company no one has ever heard of’

    The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug. 

    By Dec. 6, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    An FDA proposal could make OTC switches easier. Here’s what the industry has to say

    How the FDA’s proposal to create a new OTC approval pathway could impact the pharma industry.

    By Dec. 5, 2022
  • Addiction brain
    Image attribution tooltip
    Rafik via Getty Images

    AI company zeros in on compounds to treat addiction by rewiring the brain

    GATC Health is driving a novel approach it believes could work for several major neurological conditions.

    By Kelly Bilodeau • Dec. 5, 2022
  • Microscopic look at neurons
    Image attribution tooltip

    Koto/iStock

    Sponsored by Allucent

    Big passion for small biotech and its potential to address complex diseases

    A conversation with Teresa Nunes, chief medical officer of Allucent.

    Dec. 5, 2022
  • lightbulb breaking
    Image attribution tooltip
    Stock via Getty Images
    Opinion

    Healthcare tech’s biggest busts

    The metaverse, blockchain, DCTs and more — here are some of the most recent fails in healthcare tech.

    By Dec. 2, 2022
  • Overhead view of a person holding two white pills in their left hand and a glass of water in their right hand.
    Image attribution tooltip
    Stock via Getty Images
    Q&A

    Non-toxic and addiction free: The promise of a new pain med

    Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.

    By Dec. 1, 2022
  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020, in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    5 final FDA action dates to watch this year

    A potential flurry of regulatory activity could be on the horizon yet this year — and several key drug approvals are at stake.

    By Dec. 1, 2022
  • pills
    Image attribution tooltip
    Stock via Getty Images

    10 of our most popular articles in 2022

    Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.

    By Nov. 30, 2022
  • Alison O'Neill B&W head shot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Surface Oncology’s Dr. Alison O’Neill

    With more than two decades of experience in oncology R&D, Dr. Alison O’Neill is helping Surface unlock the potential of next-gen immunotherapies by targeting the tumor microenvironment.

    By Nov. 30, 2022
  • A team of four people wearing white lab coats stand looking at a computer in a medical science laboratory.
    Image attribution tooltip
    Stock via Getty Images

    One biotech’s approach to science-driven innovation

    Why some in the industry say fostering creativity in drug development is all about work structures.

    By Nov. 29, 2022
  • Barry Sherman
    Image attribution tooltip

    Al Dunlop/ZUMA Press/Newscom

    5 enduring mysteries of the Barry and Honey Sherman murders

    After nearly five years, the homicide case involving pharma billionaires continues to perplex investigators.

    By Nov. 28, 2022
  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical

    Executive changes at Teva, Eversana could spell commercial growth in the new year

    With their latest personnel moves, these life sciences companies are preparing for major business shifts.

    By Nov. 23, 2022
  • lab tubes
    Image attribution tooltip
    Stock via Getty Images
    Q&A

    In cancers with very low survival rates, Sellas aims higher

    The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.

    By Kelly Bilodeau • Nov. 21, 2022
  • IPO
    Image attribution tooltip
    AndreyPopov via Getty Images

    Why the biopharma ‘IPO playbook’ changed in 2022

    Biopharma IPOs have puttered in 2022, particularly compared to the record-breaking previous year, but they might be set to rebound.

    By Nov. 21, 2022
  • Person using a laptop computer on a mixed color background
    Image attribution tooltip

    TierneyMJ/Shutterstock.com

    Sponsored by ClinicalMind

    Can a formal needs assessment simplify Speaker Bureau compliance?

    In the biopharmaceutical industry, phases of innovation and change are often driven by regulatory action.

    Nov. 21, 2022
  • office red
    Image attribution tooltip
    Stock via Getty Images
    Opinion

    Hybrid work is here to stay — here’s how leaders should adjust

    Executives across the life sciences share their tips for navigating the new norm of remote work.

    By Nov. 18, 2022
  • Close up of a woman's hand holding a smart phone with a heart icon.
    Image attribution tooltip
    iStock via Getty Images

    4 pioneering social media campaigns in pharma this year

    The key to a great social media campaign is often simplicity, and these pharma companies hit the nail on the head with unique strategies that aim to educate. 

    By Nov. 17, 2022
  • Artificial intelligence in healthcare
    Image attribution tooltip
    ArtemisDiana via Getty Images

    Is AI just hype or a real revolution in pharma? It’s complicated

    Artificial intelligence can be a useful tool and will likely augment many processes in biopharma — but it's still early days, and hype is rampant.

    By Nov. 17, 2022
  • Professional headshot of Sana Alajmovic.
    Image attribution tooltip

    Permission granted by Sana Alajmovic

    Profile

    A ‘bold vision’ to prevent diabetes

    Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts. 

    By Alexandra Pecci • Nov. 15, 2022
  • COVID vaccine development
    Image attribution tooltip
    iStock via Getty Images

    4 ways to bring COVID’s ‘warp speed’ to the next era of drug development

    An IQVIA Institute for Human Data Science report outlines how companies can improve communication, recruitment, data and investing strategies to accelerate clinical trial timelines.

    By Kelly Bilodeau • Nov. 14, 2022
  • washington flag
    Image attribution tooltip
    iStock via Getty Images
    Opinion

    Why the IRA will drive up the country’s drug bill — not lower it

    On the surface, the Inflation Reduction Act is designed to lower drug prices, but its impact on innovation incentives could produce a landscape of new medicines that are costlier for patients.

    By John LaMattina • Nov. 14, 2022
  • Glen de Vries blue origin
    Image attribution tooltip
    Permission granted by Medidata
    Q&A

    The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur

    Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

    By Nov. 11, 2022